Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024  - Episode 5

Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

, , , ,

A key opinion leader offers insights and analysis on the recently presented COMMANDS trial data from the European Hematology Association 2024 conference.

EP. 1: Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification
EP. 2: Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 
EP. 3: Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies
EP. 4: Review of the COMMANDS Trial
Now Viewing
EP. 5: Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial
EP. 6: Clinical Implications of COMMANDS Trial in Clinical Practice
EP. 7: Treatment Decision-Making Based on the COMMANDS Trials
EP. 8: Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024
EP. 9: Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data
EP. 10: Safety Profile of Available Frontline Treatments LR-MDS
EP. 11: 1L treatment of lower-risk MDS beyond luspatercept
EP. 12: Sequencing Second-Line Treatments for LR-MDS
EP. 13: Perspectives of IMerge Study
EP. 14: Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024
EP. 15: EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates
EP. 16: Final Thoughts on EHA 2024 Data for Lower-Risk MDS
  • What are your perceptions of the full analysis from the COMMANDS trial?